Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial

[1]  C. Garnis,et al.  A Dynamic Oral Cancer Field: Unraveling the Underlying Biology and Its Clinical Implication , 2009, The American journal of surgical pathology.

[2]  C. MacAulay,et al.  Tracing the “At-Risk” Oral Mucosa Field with Autofluorescence: Steps Toward Clinical Impact , 2009, Cancer Prevention Research.

[3]  Neil K. Aaronson,et al.  Speech Handicap Index in patients with oral and pharyngeal cancer: Better understanding of patients' complaints , 2008, Head & neck.

[4]  Steve Scoppa,et al.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2007, Cancer Epidemiology Biomarkers & Prevention.

[5]  Pierre Lane,et al.  Direct fluorescence visualization of clinically occult high‐risk oral premalignant disease using a simple hand‐held device , 2007, Head & neck.

[6]  Calum MacAulay,et al.  Fluorescence Visualization Detection of Field Alterations in Tumor Margins of Oral Cancer Patients , 2006, Clinical Cancer Research.

[7]  G. Thomas,et al.  Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial , 2005, The Lancet.

[8]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[9]  C. R. Leemans,et al.  Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients , 2004, Clinical Cancer Research.

[10]  C. R. Leemans,et al.  Genetically Altered Fields as Origin of Locally Recurrent Head and Neck Cancer , 2004, Clinical Cancer Research.

[11]  C. R. Leemans,et al.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. , 2003, Cancer research.

[12]  C. R. Leemans,et al.  Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[14]  N D Le,et al.  Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  E. Vokes,et al.  The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity , 1996, Cancer.

[16]  R H Hruban,et al.  Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.

[17]  G. Snow,et al.  Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor , 1994, Cancer.

[18]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.